Evelo Biosciences

Evelo Biosciences is a clinical stage biotechnology company based in Cambridge, Massachusetts. With a workforce of 44 employees, the company focuses on developing groundbreaking therapies. Evelo Biosciences specializes in creating orally delivered product candidates, known as SINTAX™, which target the small intestinal axis. This unique approach leverages the SINTAX™ to influence the immune, metabolic, and neurological systems, offering a novel way to address a wide range of conditions. The company's initial product candidates, EDP1815, EDP1867, EDP2939, and EDP1908, are designed to treat inflammatory diseases and cancer, respectively. Evelo is also exploring the development of additional product candidates for other disease areas. Evelo Biosciences distinguishes itself through its innovative approach of utilizing single strains of microbes to deliver targeted pharmacological effects. The company's goal is to develop effective, safe, and affordable medicines that significantly improve the lives of patients suffering from inflammatory diseases and cancer. For more information about Evelo Biosciences and its groundbreaking therapies, please visit their website at evelobio.com.